Cerenome expects Q3 CNSide gross billings of $1.55 million
CNSY•Cerenome projected $1.55 million in Q3 2026 CNSide gross billings from 222 tests billed at list prices. It expects an annualized gross billing run rate of $10 million to $12 million in Q4 2026.
1. Billing outlook
Cerenome projected Q3 2026 CNSide gross billings of $1.55 million from 222 tests billed at list prices. It targets an annualized test volume run rate of 1,250 in Q4 2026, with initial cash collections anticipated that quarter; Medicare pricing for PLA code 0640U is targeted to take effect Jan. 1, 2027.
